IMR Press / FBL / Volume 19 / Issue 5 / DOI: 10.2741/4243

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review
Application of adipose-derived stem cells in critical limb ischemia
Show Less
1 Department of Vascular and Endovascular Surgery, Changzheng Hospital, 415 Fengyang Road, Shanghai, China
2 Department of Interventional Radiology, Tenth People's Hospital of Tongji University, 301 Yanchang Road, Shanghai, 200072, China
Academic Editor:Fei He
Front. Biosci. (Landmark Ed) 2014, 19(5), 768–776;
Published: 1 January 2014
(This article belongs to the Special Issue Cellular immunology and stem cell biology)

Peripheral artery disease is growing in global prevalence. Its most severe form, critical limb ischemia (CLI), is associated with high rates of limb loss, morbidity, and mortality. Neovascularization is the cornerstone of limb preservation in CLI. In the field of regenerative medicine, basic research and preclinical studies have been conducted using mesenchymal stem cells (MSCs) from adult tissues, including bone marrow and adipose tissue, to overcome clinical shortcomings. Adipose-derived stem cells (ASCs) display stable growth and proliferation kinetics and can differentiate into osteogenic, chondrogenic, adipogenic, myogenic or neurogenic lineages. ASCs are readily available from autologous adipose tissue, and have significant potential for tissue repair under conditions of myocardial infarction, heart failure, hind limb ischemia, and inflammation. This review highlights some of the key reports underlining the potential of ASCs, particularly in diseases involving neovascularization.

Adipose-Derived Stem Cells
Therapeutic Vasculogenesis
Therapeutic Angiogenesis
Critical Limb Ischemia
Back to top